WIXOM, Mich. -- Rockwell Medical Technologies, Inc.(Nasdaq: RMTI), a specialty pharma company focused on drug and device development in the renal market, reported today that it has added Dr. James D. Cook, an internationally recognized expert in the field of iron, to its Scientific Advisory Board (SAB). Dr. Cook has published over 200 peer-reviewed articles on all aspects of human iron metabolism with emphasis on iron absorption, internal iron kinetics and the clinical assessment of iron status in a career spanning over 40 years. Rockwell's SAB currently advises the Company on clinical development and market preparation for its proprietary iron-maintenance product SFP, currently in Phase IIb clinical trials. Rockwell's SAB consists of experts in the fields of renal anemia, iron therapy, nephrology and FDA regulatory approval.

Dr. Cook graduated from Queen's University, Canada with an M.D. degree in 1960 and M.Sc (Med) in 1963. He obtained his clinical training in Internal Medicine at Boston City Hospital and hematology training at the University of Washington, Seattle where he remained on faculty until 1975. He was then appointed the Phillips Professor of Medical Research and Director of Hematology, Department of Medicine at the Kansas University Medical Center, Kansas City, Kansas. Dr. Cook retired from teaching and clinical practice as Professor Emeritus at Kansas University in 2007.

In the late 1960s Dr. Cook, in collaboration with Dr. Joseph Eschbach, studied disorders of erythropoiesis and iron absorption in patients with kidney failure. In his distinguished career, Dr. Cook has served as Chairman on several national and international research/advisory committees including the Expert Panel on Iron, International Committee for Standardization in Hematology (1981); Subcommittee on Nutritional Anemia, American Society of Hematology (1979); Subcommittee on Iron Methodology, National Committee for Clinical and Laboratory Standards (1979-95); International Center for Control of Nutritional Anemia (ICCNA), University of Kansas Medical Center (1982-94), and Iron Subcommittee, FAO/WHO Expert Consultation on Requirements of Vitamin A, Iron, Folate and Vitamin B12 (1985). Dr. Cook has also served as a member/consultant on the Editorial Board, Journal of Nutrition (1978-1983); NIH Hematology Study Section (1983-1987), Tanzania Nutritional Anemia Consultative Group, Dar es Salaam, Tanzania (1991-92); US National Committee, International Union of Nutritional Sciences (1986-1992); Joint Micronutrient Consultative Group, Nutrition Foundation (1992-94); British Task Force on Iron Nutrition (1992-93); National Nutrition Council, Stockholm, Sweden (1993); Scientific Subcommittee on Iron and Heme, American Society of Hematology (2001- 2004); and International Federation of Clinical Chemistry Working Group on Laboratory Management of r-HuEPO Therapy (2002-2005).

Mr. Robert L. Chioini, Chairman, CEO and President of Rockwell stated, "We are excited to have added Dr. Cook to our SAB. Dr. Cook's expertise and wealth of experience in the iron field will be invaluable to Rockwell as the Company further exploits the unique properties of SFP that make it ideally suited for the oral, nutritional and parenteral and enteral administration markets. We have assembled a first-class team to help facilitate not only FDA market approval of SFP in ESRD but to also pursue regulatory approval of other SFP applications within CKD and other new markets as well."

Rockwell's current SAB consists of:

• Anatole Besarab, MD, Director of Clinical Research, Division of Nephrology and Senior Staff Physician, Henry Ford Hospital, Detroit and lead Principal Investigator for the Phase II-b dose range study.
• Rajiv Agarwal, MD, Professor of Medicine, Indiana University School of Medicine, Indianapolis.
• Richard Zager, MD, Director of Nephrology, Fred Hutchinson Cancer Research Center and Professor of Medicine, University of Washington, Seattle.
• James Cook, MD, former Phillips Professor of Medical Research and Director of Hematology, and currently Professor Emeritus, Kansas University, Kansas City, Kansas.
• Bert Spilker, PhD, MD, President Bert Spilker & Associates, LLC.
• Ajay Gupta, MD, Associate Professor of Medicine, UCLA and Charles Drew University Schools of Medicine, Los Angeles; the inventor of SFP as a parenteral iron supplement (via hemodialysis and peritoneal dialysis solutions, intravenously and as an adjunct to parenteral nutritional admixtures. Dr. Gupta is the Principal Investigator for the ongoing NIH sponsored clinical trial examining oxidative stress and inflammation in response to SFP versus IV iron.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc.(Nasdaq: RMTI), a specialty pharma company focused on drug and device development in the renal market, reported today that it has added Dr. Richard Zager, an expert in acute renal injury and renal failure to its Scientific Advisory Board (SAB). Rockwell's SAB currently advises the Company on clinical development and market preparation for its proprietary iron-maintenance product SFP, currently in Phase IIb clinical trials. Rockwell's SAB consists of experts in the fields of renal anemia, iron therapy, nephrology and FDA regulatory approval.

Dr. Zager currently serves as the Director of Nephrology at the Fred Hutchinson Cancer Research Center. He is a board certified internist and nephrologist with 35 years of clinical experience. He has supervised a NIH funded basic research laboratory for the past 30 years, with a primary interest in acute renal injury and acute renal failure. His work focuses on cellular pathways of acute oxidant and non-oxidant injury, and subsequent post-injury adaptive responses. He has had a particular interest in iron mediated renal injury, as induced by either porphyrin iron containing proteins (most notably, hemoglobin, myoglobin, or cytochrome) or by clinically employed iron - carbohydrate complexes (e.g., Fe sucrose, gluconate, dextrose, as used to treat clinical iron deficiency). He is an elected member of the Association of American Physicians. Dr. Zager graduated from Northwestern Medical School and did his post graduate medical training at UCLA Medical Center, The University of Washington in Seattle, Boston University, and Harvard Medical School.

Mr. Robert L. Chioini, Chairman, CEO and President of Rockwell stated, “We're delighted to have Dr. Zager join our team. His expertise in iron mediated biochemical and cellular effects will be invaluable as Rockwell undertakes clinical studies exploring the potential advantages of SFP over the conventional polymeric iron complexes used for intravenous administration.”

SFP, the Company's lead renal drug, is a water-soluble iron designed to provide physiological-iron-maintenance-therapy for anemic ESRD patients. SFP is delivered direct to the bloodstream of the ESRD patient, via dialysate, during each kidney dialysis treatment, maintaining optimal iron balance, avoiding liver toxicity and decreasing associated nursing and pharmaceutical IV iron administration costs. Recent academic studies have shown that more frequent maintenance doses of iron improve the therapeutic response and benefits of recombinant erythropoietin treatments.

The Company is currently conducting a Phase II-b study and sponsoring an on-going NIH-funded study in anticipation of gaining FDA market approval. Rockwell has licensed exclusive world-wide rights and has secured patents for SFP in multiple countries, including the three largest dialysis markets in the world; the United States, Japan and the European Union. The U.S. dialysis market for IV-iron delivery is approximately $500 million annually while global market potential is approximately $800 million.

Rockwell is a leading, innovative manufacturer and developer of renal drug therapies and critical products focused on improving the quality of care for dialysis patients. Dialysis is a process that duplicates kidney function for those patients who suffer from chronic kidney failure, a condition also known as end-stage-renal-disease (ESRD). There are an estimated 370,000 ESRD patients in the United States growing approximately 3-5% on average each year and approximately 2 million ESRD patients world-wide.

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "projected," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not placed on any such forward-looking statements which are based on information available to us on the date of this release. Because these forward looking statements are based upon estimates and assumptions that are subject to significant business, economic and competitive uncertainties, many of which are beyond the Company's control or are subject to change, actual results could be materially different. Factors which could cause such a difference include, without limitation, the risk factors set forth in the Company's SEC filings. The forward-looking statements should be considered in light of these risks and uncertainties. Rockwell does not undertake, and expressly disclaims any obligation, to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

(return to News Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., today announced that Robert L. Chioini, President and CEO and Thomas Klema, CFO of Rockwell Medical Technologies, Inc. will present an overview of the Company at the Barrington Research Healthcare Conference Wednesday, May 28, 2008. The conference is being held May 27-28, 2008 at the Hilton Chicago hotel in Chicago, IL.

Rockwell is a leading, innovative manufacturer and developer of renal drug therapies and critical products focused on improving the quality of care for dialysis patients. Dialysis is a process that duplicates kidney function for those patients who suffer from chronic kidney failure, a condition also known as end-stage-renal-disease (ESRD). There are an estimated 370,000 ESRD patients in the United States growing approximately 3-5% on average each year and approximately 2 million ESRD patients world-wide. Rockwell's products are used to maintain life, removing toxins and replacing nutrients in the dialysis patient's bloodstream. Rockwell is currently developing unique, proprietary renal drug therapies for both iron maintenance and carnitine supplementation utilizing its dialysate as the delivery mechanism. These exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are designed to deliver safe and effective therapy to these patients while decreasing cost.

SFP, the Company's lead renal drug, is a water-soluble iron designed to provide physiological-iron-maintenance-therapy for anemic ESRD patients. SFP is delivered direct to the bloodstream of the ESRD patient, via dialysate, during each kidney dialysis treatment, maintaining optimal iron balance, avoiding liver toxicity and decreasing associated nursing and pharmaceutical IV iron administration costs. Recent academic studies have shown that more frequent maintenance doses of iron improve the therapeutic response and benefits of recombinant erythropoietin treatments.

The Company is currently conducting a Phase II-b study and sponsoring an on-going NIH-funded study in anticipation of gaining FDA market approval. Rockwell has licensed exclusive world-wide rights and has secured patents for SFP in multiple countries, including the three largest dialysis markets in the world; the United States, Japan and the European Union. The U.S. dialysis market for IV-iron delivery is approximately $500 million annually while global market potential is approximately $800 million.

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "projected," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not placed on any such forward-looking statements which are based on information available to us on the date of this release. Because these forward looking statements are based upon estimates and assumptions that are subject to significant business, economic and competitive uncertainties, many of which are beyond the Company's control or are subject to change, actual results could be materially different. Factors which could cause such a difference include, without limitation, the risk factors set forth in the Company's SEC filings. The forward- looking statements should be considered in light of these risks and uncertainties. Rockwell does not undertake, and expressly disclaims any obligation, to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

(return to News Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative manufacturer and developer of renal drug therapies and essential dialysate products, reported record first quarter 2008 sales of $12.4 million, an increase of 31% over sales of $9.5 million in the first quarter of last year. Loss per share in the first quarter of 2008 was ($.09) compared to ($.14) in the first quarter of 2007.

First Quarter Financial Highlights

• Record quarterly revenue of $12,412,037 increased 31% or $2.9 million compared to 2007.
• Sequential revenue growth of 3.9% or $463,000 over the fourth quarter of 2007.
• Strong domestic sales growth.
• Gross profit margins rose 7.8% of sales compared to 2007's first quarter gross margin deficit.
• SG&A expense included non-cash charges for stock options and warrants of $335,000.
• SFP related R&D spending of $782,000 was 6.3% of sales.
• Net interest income of $145,000 from the investment of the proceeds of our November 2007 equity offering.
• Loss of $1.2 million compared to a loss of $1.6 million in the first quarter 2007.
• Cash position at the end of the first quarter was $10.6 million

• SFP Phase II-b Dose Ranging Study protocol modified to reflect changes to industry hemoglobin standards.
• National Institutes of Health (NIH) funded SFP study commenced enrollment.
• Initiated executive level search for a Chief Medical Officer and a Senior VP of Research and Development.

Mr. Robert L. Chioini, Chairman and CEO stated, “We continue to progress on our SFP clinical development programs during the first quarter, including commencing enrollment for an important NIH funded comparative study of SFP.”

Mr. Chioini also stated, “While our primary focus remains on the advancement of SFP and moving Rockwell into renal drug development, we continue to grow our dialysis concentrate business and build our distribution channel which provides us with the commercial platform to effectively penetrate the dialysis provider market. We are working to improve margins in our concentrate business in the upcoming quarters as we implement price increases to recover rising fuel and material costs.”

Rockwell will be hosting a conference call to review its first quarter results and to provide investors with an update on its business development efforts on Wednesday, May 7, 2008 at 11:00 am EST.

Investors are encouraged to call in several minutes in advance at (877) 675-4757 to hear the call or they may listen on the web at the following link:

http://investor.shareholder.com/media/eventdetail.cfm?mediaid=31025&c=RMTI&mediakey=C0AE09FB2CC1F3C09B9E3C3FCE2EBE95&e=0

See www.rockwellmed.com for more details and playback options.

Rockwell Medical Technologies, Inc. is a leading, innovative manufacturer and developer of renal drug therapies and critical products focused on improving the quality of care for dialysis patients. Dialysis is a process that duplicates kidney function for those patients whose kidneys have failed to work and who suffer from chronic kidney failure, a condition also known as end-stage-renal-disease (ESRD). There are an estimated 360,000 ESRD patients in the United States growing approximately 3-5% on average each year. There are approximately 2 million ESRD patients world-wide. Rockwell's products are used to maintain life, removing toxins and replacing nutrients in the dialysis patient's bloodstream. Rockwell has licensed and is currently developing proprietary renal drug therapies for both iron-delivery(SFP) and carnitine/vitamin-delivery, utilizing its dialysate as the delivery mechanism. These exclusive renal drug therapies support disease management initiatives to improve the quality of care for dialysis patients and are designed to deliver safe and effective therapy to patients while decreasing nursing time and supply cost. The Company offers the proprietary Dri-Sate® Dry Acid Concentrate Mixing System, RenalPure® Liquid Acid Concentrate, SteriLyte® Liquid Bicarbonate Concentrate, RenalPure® Powder Bicarbonate Concentrate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. When we use words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "projected," "intend" or similar expressions, or make statements regarding our intent, belief, or current expectations, we are making forward-looking statements. While we believe these forward-looking statements are reasonable, you should not place undue reliance on any such forward-looking statements which are based on information available to us on the date of this release. Because these forward looking statements are based upon estimates and assumptions that are subject to significant business, economic and competitive uncertainties, many of which are beyond our control or are subject to change, actual results could be materially different. Factors which could cause such a difference include, without limitation, the risk factors and other risks and uncertainties set forth in the Company's SEC filings, including its Form 10-K for the year ended December 31, 2007 and its Forms 10-Q filed during 2008. The forward- looking statements should be considered in light of these risks and uncertainties. We do not undertake, and expressly disclaim any obligation, to update or alter our statements whether as a result of new information, future events or otherwise, except as required by law.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., announced today that it will hold an investor conference call on Wednesday, May 7, 2008 at 11:00AM EST to discuss its first quarter 2008 results and to provide investors with a business update. Robert Chioini, Chairman and CEO, and Thomas Klema, CFO, will be hosting the call to review Rockwell's results and answer questions from investors.

The conference call will be held on:

Wednesday, May 7, 2008
Starting Time 11:00 a.m. Eastern
Dial in Number: 877-675-4757

When calling in please refer to the Rockwell Medical Technologies Investor Conference Call and provide the operator with your name and company affiliation.

Investors who prefer to participate using the internet may access the following link: http://investor.shareholder.com/media/eventdetail.cfm?mediaid=31025&c=RMTI&mediakey=C0AE09FB2CC1F3C09B9E3C3FCE2EBE95&e=0

International Investors may dial in directly on 719-325-4889.

Investors who are unable to listen to the Rockwell investor conference call will be able to access a replay via our web site at www.rockwellmed.com.

We appreciate your interest in Rockwell.

(return to News Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative manufacturer and developer of renal drug therapies and essential dialysate products, reported record fourth quarter 2007 sales of $11.95 million, up 29.5% as compared to $9.2 million for the same period of 2006. Loss per share for the fourth quarter was ($.09) vs. ($.10) for the same period of 2006.

Year end 2007 results were highlighted by record sales of $43 million, increasing over 50% as compared to $28.6 million in 2006. Loss for the year ended 2007 was ($.32) vs. ($.41) in 2006.

Highlights:

Fourth Quarter

• Record quarterly revenue $11,948,905 up 29.5% over fourth quarter 2006.
• Sequential revenue growth of 7.9% over third quarter 2007.
• Loss per share ($.09) a $.01 improvement compared to ($.10) in 2006.

• Revenue increased to $43 million, up 50% in 2007 compared to 2006.
• Domestic sales increased greater than 70% in 2007.
• Research and development costs were $3.26 million in 2007.
• Loss per share ($.32) a $.09 improvement compared to ($.41) in 2006.
• RMTI stock upgraded to the Nasdaq Global Market Exchange in January 2007.

• Commenced Phase II-b clinical study
• Raised gross proceeds of $12.9 million in November 2007 to fund on-going FDA clinical trial.
• Completed protocol to begin NIH-funded study.
• Completed pre-clinical safety pharmacology and toxicology studies for SFP.
• Received final safety pharm/toxicology reports demonstrating strong safety profile for SFP.
• Patent grants received for Japan and Mexico.

Mr. Robert L. Chioini, Chairman and CEO stated, “Our fourth quarter marked a significant milestone for our SFP drug development program. We commenced our Phase II-b human clinical study and successfully completed a capital raise of nearly $13 million, which we expect will fund our current FDA clinical development program.”

Mr. Chioini also stated, “Our concentrate sales increased significantly in 2007 but rising inflation in our primary cost drivers temporarily pressured our gross margins in the fourth quarter. Going forward, we anticipate margin improvement in our concentrate business as we pass on inflationary costs to our customer base, and we expect to continue to solidify our market position which is currently over 26% of the dialysis provider market.”

Rockwell will be hosting a conference call to review its 2007 and fourth quarter results on Thursday, March 6, 2008 at 11:00 am EST. Investors are encouraged to call in several minutes in advance at (888) 661-5174 to hear the call or they may listen on the web at the following link: http://investor.shareholder.com/media/eventdetail.cfm?mediaid=30039&c=RMTI&mediakey=2ABCD2DFF357359EB5B2BDFF66F876B3&e=0

See www.rockwellmed.com for more details and playback options.

Rockwell Medical Technologies, Inc. is a leading, innovative manufacturer and developer of renal drug therapies and critical products focused on improving the quality of care for dialysis patients. Dialysis is a process that duplicates kidney function for those patients whose kidneys have failed to work and who suffer from chronic kidney failure, a condition also known as end-stage-renal-disease (ESRD). There are an estimated 360,000 ESRD patients in the United States growing approximately 3-5% on average each year. There are approximately 2 million ESRD patients world-wide. Rockwell's products are used to maintain life, removing toxins and replacing nutrients in the dialysis patient's bloodstream. Rockwell has licensed and is currently developing proprietary renal drug therapies for both iron-delivery and carnitine/vitamin-delivery, utilizing its dialysate as the delivery mechanism. These exclusive renal drug therapies support disease management initiatives to improve the quality of care for dialysis patients and are designed to deliver safe and effective therapy to patients while decreasing nursing time and supply cost. The Company offers the proprietary Dri-Sate® Dry Acid Concentrate Mixing System, RenalPure® Liquid Acid Concentrate, SteriLyte® Liquid Bicarbonate Concentrate, RenalPure® Powder Bicarbonate Concentrate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. When we use words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "projected," "intend" or similar expressions, or make statements regarding our intent, belief, or current expectations, we are making forward-looking statements. While we believe these forward-looking statements are reasonable, you should not place undue reliance on any such forward-looking statements which are based on information available to us on the date of this release. Because these forward looking statements are based upon estimates and assumptions that are subject to significant business, economic and competitive uncertainties, many of which are beyond our control or are subject to change, actual results could be materially different. Factors which could cause such a difference include, without limitation, the risk factors and other risks and uncertainties set forth in the Company's SEC filings, including its Form 10-KSB for the year ended December 31, 2006 and its Forms 10-Q filed during 2007. The forward- looking statements should be considered in light of these risks and uncertainties. We do not undertake, and expressly disclaim any obligation, to update or alter our statements whether as a result of new information, future events or otherwise, except as required by law.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., announced today that it will hold an investor conference call on Thursday, March 6, 2008 at 11:00AM EST to discuss its fourth quarter and 2007 results and to provide investors with a business update. Robert Chioini, Chairman and CEO, and Thomas Klema, CFO, will be hosting the call to review Rockwell's results and answer questions from investors.

The conference call will be held on:

Thursday, March 6, 2008
Starting Time 11:00 a.m. Eastern
Dial in Number: (888) 661-5174

When calling in please refer to the Rockwell Medical Technologies Investor Conference Call and provide the operator with your name and company affiliation.

Investors who prefer to participate using the internet may access the following link: http://investor.shareholder.com/media/eventdetail.cfm?mediaid=30039&c=RMTI&mediakey=2ABCD2DFF357359EB5B2BDFF66F876B3&e=0

International Investors may dial in directly on (913) 905-3226.

Investors who are unable to listen to the Rockwell investor conference call will be able to access a replay via our web site at www.rockwellmed.com.

We appreciate your interest in Rockwell.

(return to News Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative manufacturer and developer of renal drug therapies and essential dialysate products focused on the end-stage-renal-disease (ESRD) market, announced today that the National Institutes of Health (NIH) sponsored clinical study for Soluble Ferric Pyrophosphate (SFP), Rockwell's physiological iron-maintenance-therapy drug, has entered active treatment phase with the initiation of dosing.

The clinical design is a 9-month, 30-patient, prospective, randomized, open-label, multi-center, controlled clinical trial of the safety and efficacy of physiological iron maintenance in ESRD subjects by delivery of SFP via hemodialysate. ESRD subjects receiving maintenance hemodialysis will be enrolled and randomized to receive hemodialysis using dialysate solutions with SFP or conventional solutions lacking iron at every dialysis session with the goal of maintaining iron balance within a tight hemoglobin range.

• Primary End-points:
• Efficacy: The amount of therapeutic IV iron needed by subjects in the group receiving SFP in their dialysate versus those who do not.
• Safety: Safety and tolerability determined by clinically significant changes on vital signs, clinical laboratory measures, and incidence and severity of adverse events.

• Secondary End-points:
• Hemoglobin maintenance and variability within optimal target range.
• Efficiency of iron delivery to the erythron.
• Incidence and time to development of iron deficiency and iron overload.
• Markers of inflammation and oxidative stress.

Robert L. Chioini, Chairman and CEO of Rockwell stated, “Beginning the successful dosing of dialysis patients in this NIH sponsored study is another significant milestone in our clinical path for gaining FDA market approval for SFP. We expect to share news of our clinical progress as it becomes available.”

About National Institutes of Health

The National Institutes of Health (NIH), http://www.nih.gov, a part of the US Department of Health and Human Services, is the primary federal agency for conducting and supporting medical research. Helping to lead the way toward important medical discoveries that improve people's health and save lives, NIH sponsored scientists investigate ways to prevent disease as well as the causes, treatments, and even cures for common and rare diseases.

About Soluble Ferric Pyrophosphate (SFP)

Rockwell's proprietary iron-delivery product, SFP, is a soluble form of iron designed to provide physiological iron maintenance therapy in ESRD patients by delivering iron via dialysate during dialysis treatments. SFP is a highly stable and non-polymeric iron salt and is designed to be administered directly into the bloodstream, overcoming the need for iron release from reticuloendothelial stores in the liver and other organs. The ferric iron core is tightly chelated to a pyrophosphate shell that facilities transfer of iron from transferrin to ferritin, by-passing the liver. Compared to intravenous (IV) iron administration, previous human clinical study results indicate that SFP can deliver iron (via dialysate) safely and effectively and can maintain iron balance in dialysis patients within the target range, while at the same time decreasing associated nursing and pharmaceutical IV iron administration costs. Recent academic studies have shown that more frequent maintenance doses of iron improve the therapeutic benefits of recombinant erythropoietin treatments.

Rockwell has licensed the exclusive world-wide rights to SFP and is seeking FDA market approval. Patents for SFP have been secured in the United States, Japan and the European Union covering the largest commercial markets for iron supplementation. Rockwell estimates that the U.S. dialysis market for IV iron delivery is approximately $480 million annually while the global market potential is approximately $800 million annually.

About Rockwell Medical Technologies, Inc.

Rockwell Medical Technologies, Inc. is a leading, innovative manufacturer and developer of concentrates and specialty pharmaceuticals focused on improving the quality of care for dialysis patients. Dialysis is a process that duplicates kidney function for those patients whose kidneys have failed to work and who suffer from chronic kidney failure, a condition also known as end-stage-renal-disease (ESRD). There are an estimated 360,000 ESRD patients in the United States growing approximately 4-5% on average each year. There are approximately 2 million ESRD patients world-wide. Rockwell's products are used to maintain life, cleaning blood and replacing nutrients in the dialysis patient's bloodstream. Rockwell has licensed and is currently developing proprietary formulations for both iron-delivery and carnitine/vitamin-delivery utilizing its dialysate as the delivery mechanism. These novel technologies are designed to deliver safe and effective renal therapy to ESRD patients while decreasing nursing time and supply cost. The Company offers the proprietary Dri-Sate® Dry Acid Concentrate Mixing System, RenalPure® Liquid Acid Concentrate, SteriLyte® Liquid Bicarbonate Concentrate, RenalPure® Powder Bicarbonate Concentrate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. When we use words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "projected," "intend" or similar expressions, or make statements regarding our intent, belief, or current expectations, we are making forward- looking statements. While we believe these forward-looking statements are reasonable, you should not place undue reliance on any such forward-looking statements which are based on information available to us on the date of this release. Because these forward looking statements are based upon estimates and assumptions that are subject to significant business, economic and competitive uncertainties, many of which are beyond our control or are subject to change, actual results could be materially different. Factors which could cause such a difference include, without limitation, the risk factors set forth in the Company's SEC filings, including its Form 10-Q for the quarter ended September 30, 2007 and its Form 10-KSB for the year ended December 31, 2006. The forward- looking statements should be considered in light of these risks and uncertainties. We do not undertake, and expressly disclaim any obligation, to update or alter our statements whether as a result of new information, future events or otherwise, except as required by law.

(return to News Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative manufacturer and developer of renal drug therapies and essential dialysate products focused on the end-stage-renal-disease (ESRD) market, announced today that patient enrollment has started for a National Institutes of Health (NIH) sponsored clinical study for Soluble Ferric Pyrophosphate (SFP), the Company's physiological iron-maintenance-therapy drug.

Dr. Mordechai S. Nosrati, MD, Associate Professor of Clinical Medicine at Keck-USC School of Medicine and co-principal investigator stated, “SFP in dialysate allows for the slow infusion of iron over a 4-hour dialysis session and physiologically mimics how the human body normally handles and processes dietary iron, thereby potentially mitigating the side effects associated with intravenous iron such as release of free iron and excess storage of iron in the liver. I'm very excited to participate in the study of this revolutionary advancement in iron delivery.”

The NIH sponsored study is a 9-month, 30-patient, two-site, randomized, controlled, clinical study that will examine maintenance of hemoglobin, iron parameters, need for intravenous iron and oxidative stress markers in patients receiving SFP via dialysate versus patients receiving conventional iron-free dialysate. New data from this important study is expected to be published in late 2008.

About National Institutes of Health

The National Institutes of Health (NIH), http://www.nih.gov, a part of the US Department of Health and Human Services, is the primary federal agency for conducting and supporting medical research. Helping to lead the way toward important medical discoveries that improve people's health and save lives, NIH sponsored scientists investigate ways to prevent disease as well as the causes, treatments, and even cures for common and rare diseases.

About Soluble Ferric Pyrophosphate (SFP)

Rockwell's proprietary iron-delivery product, SFP, is a soluble form of iron designed to provide physiological iron maintenance therapy in ESRD patients by delivering iron via dialysate during dialysis treatments. SFP is a highly stable and non-polymeric iron salt and is designed to be administered directly into the bloodstream, overcoming the need for iron release from reticuloendothelial stores in the liver and other organs. The ferric iron core is tightly chelated to a pyrophosphate shell that facilities transfer of iron from transferrin to ferritin, by-passing the liver. Compared to intravenous (IV) iron administration, previous human clinical study results indicate that SFP can deliver iron (via dialysate) safely and effectively and can maintain iron balance in dialysis patients within the target range, while at the same time decreasing associated nursing and pharmaceutical IV iron administration costs. Recent academic studies have shown that more frequent maintenance doses of iron improve the therapeutic benefits of recombinant erythropoietin treatments.

Rockwell has licensed the exclusive world-wide rights to SFP and is seeking FDA market approval. Patents for SFP have been secured in the United States, Japan and the European Union covering the largest commercial markets for iron supplementation. Rockwell estimates that the U.S. dialysis market for IV iron delivery is approximately $480 million annually while the global market potential is approximately $800 million annually.

About Rockwell Medical Technologies, Inc.

Rockwell Medical Technologies, Inc. is a leading, innovative manufacturer and developer of concentrates and specialty pharmaceuticals focused on improving the quality of care for dialysis patients. Dialysis is a process that duplicates kidney function for those patients whose kidneys have failed to work and who suffer from chronic kidney failure, a condition also known as end-stage-renal-disease (ESRD). There are an estimated 360,000 ESRD patients in the United States growing approximately 4-5% on average each year. There are approximately 2 million ESRD patients world-wide. Rockwell's products are used to maintain life, cleaning blood and replacing nutrients in the dialysis patient's bloodstream. Rockwell has licensed and is currently developing proprietary formulations for both iron-delivery and carnitine/vitamin-delivery utilizing its dialysate as the delivery mechanism. These novel technologies are designed to deliver safe and effective renal therapy to ESRD patients while decreasing nursing time and supply cost. The Company offers the proprietary Dri-Sate® Dry Acid Concentrate Mixing System, RenalPure® Liquid Acid Concentrate, SteriLyte® Liquid Bicarbonate Concentrate, RenalPure® Powder Bicarbonate Concentrate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. When we use words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "projected," "intend" or similar expressions, or make statements regarding our intent, belief, or current expectations, we are making forward- looking statements. While we believe these forward-looking statements are reasonable, you should not place undue reliance on any such forward-looking statements which are based on information available to us on the date of this release. Because these forward looking statements are based upon estimates and assumptions that are subject to significant business, economic and competitive uncertainties, many of which are beyond our control or are subject to change, actual results could be materially different. Factors which could cause such a difference include, without limitation, the risk factors set forth in the Company's SEC filings, including its Form 10-Q for the quarter ended September 30, 2007 and its Form 10-KSB for the year ended December 31, 2006. The forward-looking statements should be considered in light of these risks and uncertainties. We do not undertake, and expressly disclaim any obligation, to update or alter our statements whether as a result of new information, future events or otherwise, except as required by law.

(return to News Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative manufacturer and developer of renal drug therapies and essential dialysate products, reported today that the FDA has approved initiation of a National Institutes of Health (NIH) sponsored clinical study for Rockwell's proprietary drug-delivery product SFP for chronic hemodialysis patients.

The NIH sponsored study is a 9-month, 30 patient, two site, randomized, controlled, clinical study that will examine maintenance of hemoglobin, iron parameters, need for intravenous iron and oxidative stress markers in patients receiving SFP via dialysate versus patients receiving conventional iron-free dialysate. Patients in both groups are eligible to receive intermittent intravenous (IV) iron sucrose per protocol if iron deficiency develops. The NIH sponsored study is being conducted by independent investigators and is scheduled to begin shortly with results expected to be published late in 2008.

Dr. Ajay Gupta, lead principal investigator and inventor of SFP stated, “This study will examine the hypothesis that SFP maintains iron balance and hemoglobin while significantly reducing the need for supplemental IV iron and without causing oxidant stress and inflammation.”

The National Institutes of Health (NIH), a part of the US Department of Health and Human Services, is the primary federal agency for conducting and supporting medical research. Helping to lead the way toward important medical discoveries that improve health and save lives, NIH sponsored scientists investigate ways to prevent disease as well as the causes, treatments, and even cures for common and rare diseases.

About SFP (Soluble Ferric Pyrophosphate) - Rockwell's Lead Renal Drug Product

SFP is a water soluble form of iron designed to provide physiological-iron-maintenance-therapy for anemic ESRD patients. SFP is uniquely delivered via dialysate directly to the bloodstream, during each kidney dialysis treatment. The physiological mode of action and ease of delivery of SFP is a highly stable, non-polymeric, simple iron salt that is administered directly into the bloodstream, avoiding liver build-up and toxicity thus overcoming the need for iron release from reticuloendothelial stores in the liver and other organs. The ferric iron core is tightly chelated to a pyrophosphate shell which facilitates transfer of iron from transferrin to ferritin, bypassing the liver entirely. Based on results of an initial Phase II clinical study and compared to IV iron administration, SFP delivered via dialysate, has shown to be a safe and effective method for maintaining optimal iron balance in dialysis patients while at the same time reducing nursing and physician time and pharmaceutical IV iron costs currently associated with IV iron administration. Furthermore, recent academic studies have shown that more frequent maintenance doses of iron improve the therapeutic response and benefits of recombinant erythropoietin treatments.

Rockwell has licensed the exclusive world-wide rights to SFP and is collaborating with the FDA in its development. Rockwell has secured patents for SFP in multiple countries, including the United States, Japan, and the European Union, covering the largest commercial markets in the world for dialysis and iron supplementation. The Company has patents issued and pending in a number of other countries as well.

Rockwell estimates the current U.S. IV-iron market is $480 million and the global IV-iron market is approximately $750 million. The Company believes the U.S IV-iron market has the potential to grow to $1 billion within the next 10 years while the world-wide market could reach $1.5 billion. Rockwell's dialysate products are used as the delivery method for SFP. Rockwell's current share of the U.S. dialysate market is estimated to be 26%.

About Rockwell Medical

Rockwell Medical Technologies, Inc. is a leading, innovative manufacturer and developer of renal drug therapies and critical products focused on improving the quality of care for dialysis patients. Dialysis is a process that duplicates kidney function for those patients whose kidneys have failed to work and who suffer from chronic kidney failure, a condition also known as end-stage-renal-disease (ESRD). There are an estimated 360,000 ESRD patients in the United States growing approximately 4-5% on average each year. There are approximately 2 million ESRD patients world-wide. Rockwell's products are used to maintain life, removing toxins and replacing nutrients in the dialysis patient's bloodstream. Rockwell has licensed and is currently developing proprietary renal drug therapies for both iron-delivery and carnitine/vitamin-delivery, utilizing its dialysate as the delivery mechanism. These exclusive renal drug therapies support disease management initiatives to improve the quality of care for dialysis patients and are designed to deliver safe and effective therapy to patients while decreasing nursing time and supply cost. The Company offers the proprietary Dri-Sate® Dry Acid Concentrate Mixing System, RenalPure® Liquid Acid Concentrate, SteriLyte® Liquid Bicarbonate Concentrate, RenalPure® Powder Bicarbonate Concentrate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. When we use words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "projected," "intend" or similar expressions, or make statements regarding our intent, belief, or current expectations, we are making forward-looking statements. While we believe these forward-looking statements are reasonable, you should not place undue reliance on any such forward-looking statements which are based on information available to us on the date of this release. Because these forward looking statements are based upon estimates and assumptions that are subject to significant business, economic and competitive uncertainties, many of which are beyond our control or are subject to change, actual results could be materially different. Factors which could cause such a difference include, without limitation, the risk factors set forth in the Company's SEC filings, including its Form 10-Q for the quarter ended September 30, 2007 and its Form 10-KSB for the year ended December 31, 2006. The forward- looking statements should be considered in light of these risks and uncertainties. We do not undertake, and expressly disclaim any obligation, to update or alter our statements whether as a result of new information, future events or otherwise, except as required by law.

(return to News Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative manufacturer and developer of renal drug therapies and essential dialysate products, announced today that it has raised $12,950,000 in gross proceeds from a private placement of its common shares.

The private placement consisted of several institutional investors and the unit offering price of $6.00 was comprised of one share of common stock and a warrant to purchase 0.50 shares of common stock. The Company issued 2,158,337 common shares at $6.00 and issued warrants to purchase 1,079,169 common shares at an exercise price of $7.18.

Robert Chioini, Rockwell's CEO, commented “The $12.7 million in net proceeds is expected to fund the remaining expenses relating to the development and approval of our proprietary iron maintenance therapy drug, SFP (Soluble Ferric Pyrophosphate), used to treat iron deficiency in anemic dialysis patients.”

About Rockwell Medical

Rockwell Medical Technologies, Inc. is a leading, innovative manufacturer and developer of renal drug therapies and critical products focused on improving the quality of care for dialysis patients. Dialysis is a process that duplicates kidney function for those patients whose kidneys have failed to work and who suffer from chronic kidney failure, a condition also known as end-stage-renal-disease (ESRD). There are an estimated 360,000 ESRD patients in the United States growing approximately 4-5% on average each year. There are approximately 2 million ESRD patients world-wide. Rockwell's products are used to maintain life, removing toxins and replacing nutrients in the dialysis patient's bloodstream. Rockwell has licensed and is currently developing proprietary renal drug therapies for both iron-delivery and carnitine/vitamin-delivery, utilizing its dialysate as the delivery mechanism. These exclusive renal drug therapies support disease management initiatives to improve the quality of care for dialysis patients and are designed to deliver safe and effective therapy to patients while decreasing nursing time and supply cost. The Company offers the proprietary Dri-Sate® Dry Acid Concentrate Mixing System, RenalPure® Liquid Acid Concentrate, SteriLyte® Liquid Bicarbonate Concentrate, RenalPure® Powder Bicarbonate Concentrate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

About the Securities Issued

The securities sold in this private placement have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. As part of the transaction, the Company has agreed to file a resale registration statement on Form S-3 with the Securities and Exchange Commission within 45 days for purposes of registering the resale of the shares of common stock, and the shares of common stock underlying the warrants, issued in the offering.

This notice is issued pursuant to Rule 135c under the Securities Act of 1933 and does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state. Any offering of the securities under the resale registration statement will only be by means of a prospectus.

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. When we use words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "projected," "intend" or similar expressions, or make statements regarding our intent, belief, or current expectations, we are making forward-looking statements. While we believe these forward-looking statements are reasonable, you should not place undue reliance on any such forward-looking statements which are based on information available to us on the date of this release. Because these forward-looking statements are based upon estimates and assumptions that are subject to significant business, economic and competitive uncertainties, many of which are beyond our control or are subject to change, actual results could be materially different. Factors which could cause such a difference include, without limitation, the risk factors set forth in the Company's SEC filings, including its Form 10-Q for the quarter ended September 30, 2007 and its Form 10-KSB for the year ended December 31, 2006. The forward-looking statements should be considered in light of these risks and uncertainties. We do not undertake, and expressly disclaim any obligation, to update or alter our statements whether as a result of new information, future events or otherwise, except as required by law.

(return to News Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative manufacturer and developer of renal drug therapies and essential dialysate products, reported record quarterly sales of $11.1 million for the third quarter of 2007, up 50% over the third quarter of 2006. Sales for the first nine months of 2007 increased 60% compared to the first nine months of 2006. Third quarter loss per share was ($.04) compared to ($.14) in the third quarter last year. Rockwell's third quarter loss of ($432,912) included research and development expense of $735,393 for its physiological iron maintenance therapy drug (SFP).

Third Quarter Highlights:

• Sales increased $11.7 million or 60.2% vs. year ago.
• Domestic sales increased by 72% in the first nine months of 2007 vs. year ago.
• Net loss of ($2.6) million or ($.22) per share included R&D costs of $2.3 million.
• Net loss of ($.22) per share improved $.09 per share compared to the first nine months of 2006.
• Upgraded to the Nasdaq Global Market Exchange.

• Sales increased 66% in the first half of 2007 compared to the first half of 2006.
• Domestic dialysis centers serviced increased over 50% in 2007.
• Net Loss of ($2.1) million included R&D expense of $1.6 million.
• Upgraded to the Nasdaq Global Market Exchange.

• Commenced enrollment and dosing of SFP Phase II-b human clinical trial.
• Completed pre-clinical safety pharmacology and toxicology studies for SFP.
• Received final safety pharmacology and toxicology reports demonstrating a strong safety profile for SFP.
• Granted SFP international patents in Japan and Mexico.

“Third quarter results were in line with our expectations reflecting substantial domestic market share gains, strong sequential sales growth and margin improvements over year ago levels, despite rising inflation on several key cost drivers including fuel and core raw material costs,” stated Mr. Robert L. Chioini, Chairman and Chief Executive Officer.

Mr. Chioini also commented on SFP, “SFP is our lead renal drug therapy candidate offering high sales and earnings potential world-wide, and we achieved a significant milestone in Q3 this year when we began dosing patients in our Phase II-b clinical trial for SFP. Upon completing this study, we anticipate initiating final Phase III development and ultimately gaining FDA market approval.”

Rockwell will be hosting a conference call to review its third quarter results on Thursday, November 8, 2007 at 11:00 am EST. Investors are encouraged to call in several minutes in advance at (800) 776-0087 to hear the call or they may listen on the web at the following link: http://investor.shareholder.com/media/eventdetail.cfm?mediaid=28092&c=RMTI&mediakey=78D663E75CC8CBE67E9D20F7EE8FE739&e=0

See www.rockwellmed.com for more details and playback options.

About Rockwell Medical

Rockwell Medical Technologies, Inc. is a leading, innovative manufacturer and developer of renal drug therapies and critical products focused on improving the quality of care for dialysis patients. Dialysis is a process that duplicates kidney function for those patients whose kidneys have failed to work and who suffer from chronic kidney failure, a condition also known as end-stage-renal-disease (ESRD). There are an estimated 360,000 ESRD patients in the United States growing approximately 4-5% on average each year. There are approximately 2 million ESRD patients world-wide. Rockwell's products are used to maintain life, removing toxins and replacing nutrients in the dialysis patient's bloodstream. Rockwell has licensed and is currently developing proprietary renal drug therapies for both iron-delivery and carnitine/vitamin-delivery, utilizing its dialysate as the delivery mechanism. These exclusive renal drug therapies support disease management initiatives to improve the quality of care for dialysis patients and are designed to deliver safe and effective therapy to patients while decreasing nursing time and supply cost. The Company offers the proprietary Dri-Sate® Dry Acid Concentrate Mixing System, RenalPure® Liquid Acid Concentrate, SteriLyte® Liquid Bicarbonate Concentrate, RenalPure® Powder Bicarbonate Concentrate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. When we use words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "projected," "intend" or similar expressions, or make statements regarding our intent, belief, or current expectations, we are making forward-looking statements. While we believe these forward-looking statements are reasonable, you should not place undue reliance on any such forward-looking statements which are based on information available to us on the date of this release. Because these forward looking statements are based upon estimates and assumptions that are subject to significant business, economic and competitive uncertainties, many of which are beyond our control or are subject to change, actual results could be materially different. Factors which could cause such a difference include, without limitation, the risk factors set forth in the Company's SEC filings, including its Form 10-Q for the quarter ended September 30, 2007 and its Form 10-KSB for the year ended December 31, 2006. The forward- looking statements should be considered in light of these risks and uncertainties. We do not undertake, and expressly disclaim any obligation, to update or alter our statements whether as a result of new information, future events or otherwise, except as required by law.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative manufacturer and developer of renal drug therapies and essential dialysate products, focused on the end-stage-renal-disease (ESRD) market, today announced that Robert L. Chioini, President and CEO of Rockwell will present an overview of the Company at the JMP Securities Healthcare Focus Conference at 12:00pm EST on Tuesday, November 13, 2007. Mr. Chioini will provide investors with an overview of Rockwell and its lead renal drug therapy product, SFP.

Investors may view the webcast via http://www.wsw.com/webcast/jmp5/rmti/

Investors may also access the webcast via Rockwell's website at
http://www.rockwellmed.com/invest.htm

Audio replay of this webcast will be archived and available for replay for two weeks following the conference.

About Rockwell Medical

Rockwell Medical Technologies, Inc. is a leading, innovative manufacturer and developer of renal drug therapies and critical products focused on improving the quality of care for dialysis patients. Rockwell's products are used to maintain life, removing toxins and replacing nutrients in the dialysis patient's bloodstream.

Rockwell has licensed and is currently developing proprietary renal drug therapies for both iron-delivery and carnitine/vitamin-delivery utilizing its dialysate as the delivery mechanism. These exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are designed to deliver safe and effective therapy to these patients while decreasing drug administration cost.

About Soluble Ferric Pyrophosphate (SFP) - Rockwell's Lead Renal Drug Therapy Product

SFP is a water soluble form of iron designed to provide physiological-iron-maintenance-therapy for anemic ESRD patients. SFP (iron) is uniquely delivered via dialysate directly to the bloodstream, during each kidney dialysis treatment. SFP is a highly stable, non-polymeric iron salt that is administered directly into the bloodstream, avoiding liver toxicity build-up thus overcoming the need for iron release from reticuloendothelial stores in the liver and other organs. The ferric iron core is tightly chelated to a pyrophosphate shell which facilitates transfer of iron from transferrin to ferritin, bypassing the liver entirely.

Based on an earlier FDA Phase II clinical study, SFP delivered via dialysate, was shown to be a safe and effective method for maintaining optimal iron balance in dialysis patients while at the same time decreasing associated nursing and pharmaceutical IV iron administration costs.

(return to News Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative manufacturer and developer of renal drug therapies and essential dialysate products, focused on the end-stage-renal-disease (ESRD) market, reported that a Mexican patent was granted for its proprietary drug, Soluble Ferric Pyrophosphate (SFP). The Mexican SFP patent grant covers the method and pharmaceutical composition for iron delivery administered in hemodialysis and peritoneal dialysis patients.

Mr. Robert L. Chioini, Chairman, CEO and President of Rockwell stated, “We are pleased to add Mexico, estimated to be the 8th largest ESRD market in the world, to further strengthen and protect our proprietary intellectual property for SFP worldwide. In conjunction with the successful completion of our SFP clinical development program, we look to expand into the worldwide markets through the development of our own distribution channels and/or with an established international marketing partner.”

About Soluble Ferric Pyrophosphate (SFP) - Rockwell's Lead Renal Drug Therapy

SFP is a water soluble form of iron designed to provide physiological-iron-maintenance-therapy for anemic ESRD patients. SFP (iron) is uniquely delivered via dialysate directly to the bloodstream, during each kidney dialysis treatment. SFP is a highly stable, non-polymeric iron salt that is administered directly into the bloodstream, avoiding liver toxicity build-up thus overcoming the need for iron release from reticuloendothelial stores in the liver and other organs. The ferric iron core is tightly chelated to a pyrophosphate shell which facilitates transfer of iron from transferrin to ferritin, bypassing the liver entirely.

Based on previous FDA Phase II clinical study results and compared to intravenous (IV) iron administration, SFP delivered via dialysate, has shown to be a safe and effective method for maintaining optimal iron balance in dialysis patients while at the same time decreasing associated nursing and pharmaceutical IV iron administration costs. Furthermore, recent academic studies have shown that more frequent maintenance doses of iron improve the therapeutic response and benefits of recombinant erythropoietin treatments.

Rockwell has licensed the exclusive world-wide rights to SFP and is collaborating with the FDA in its development. Rockwell has secured patents for SFP in multiple countries, including the United States, Japan, and the European Union, covering the largest commercial markets for iron supplementation in the world. Rockwell has issued and pending patents in a number of other markets as well. Rockwell estimates that the U.S. dialysis market for IV-iron delivery is approximately $450 million annually while global market potential is approximately $750 million.

About Rockwell Medical

Rockwell Medical Technologies, Inc. is a leading, innovative manufacturer and developer of renal drug therapies and critical products focused on improving the quality of care for dialysis patients. Dialysis is a process that duplicates kidney function for those patients who suffer from chronic kidney failure, a condition also known as end-stage-renal-disease (ESRD). There are an estimated 360,000 ESRD patients in the United States growing approximately 4-5% on average each year. There are approximately 1.6 million ESRD patients world-wide. Rockwell's products are used to maintain life, removing toxins and replacing nutrients in the dialysis patient's bloodstream. Rockwell has licensed and is currently developing proprietary renal drug therapies for both iron-delivery and carnitine/vitamin-delivery utilizing its dialysate as the delivery mechanism. These exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are designed to deliver safe and effective therapy to these patients while decreasing nursing time and supply cost. The Company offers the proprietary Dri-Sate® Dry Acid Concentrate Mixing System, RenalPure® Liquid Acid Concentrate, SteriLyte® Liquid Bicarbonate Concentrate, RenalPure® Powder Bicarbonate Concentrate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. When we use words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "projected," "intend" or similar expressions, or make statements regarding our intent, belief, or current expectations, we are making forward-looking statements. While we believe these forward-looking statements are reasonable, you should not place undue reliance on any such forward-looking statements which are based on information available to us on the date of this release. Because these forward looking statements are based upon estimates and assumptions that are subject to significant business, economic and competitive uncertainties, many of which are beyond our control or are subject to change, actual results could be materially different. Factors which could cause such a difference include, without limitation, the risk factors set forth in the Company's SEC filings, including its Form 10-Q for the quarter ended June 30, 2007 and its Form 10-KSB for the year ended December 31, 2006. The forward-looking statements should be considered in light of these risks and uncertainties. We do not undertake, and expressly disclaim any obligation, to update or alter our statements whether as a result of new information, future events or otherwise, except as required by law.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., announced today that it will hold an investor conference call on Thursday, November 8, 2007 at 11:00AM EST to discuss its third quarter results and to provide investors with a business update. Robert Chioini, Chairman and CEO, and Thomas Klema, CFO, will be hosting the call to review Rockwell's results and answer questions from investors.

The conference will be held on:

Thursday, November 8, 2007
Starting Time 11:00 AM Eastern
Dial in Number: (877) 776-0087

When calling in please refer to the Rockwell Medical Technologies Investor Conference Call and provide the operator with your name and company affiliation.

Investors who prefer to participate using the internet may access the following link:
http://investor.shareholder.com/media/eventdetail.cfm?mediaid=28092&c=RMTI&mediakey=78D663E75CC8CBE67E9D20F7EE8FE739&e=0

International Investors may dial in directly on (913) 312-1427.

Investors who are unable to listen to the Rockwell investor conference call will be able to access a replay via our web site at http://www.rockwellmed.com .

We appreciate your interest in Rockwell.

(return to News Index)

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative manufacturer and developer of concentrates and specialty pharmaceuticals focused on the end-stage-renal-disease market (ESRD), announced today that it has begun dosing patients in its Phase IIb Dose-Ranging Clinical Study for Soluble Ferric Pyrophosphate (SFP), the Company's physiological iron-maintenance-therapy drug.

The Phase IIb Clinical Design is a double-blind, multi-center, randomized, placebo-controlled, nine-month study consisting of up to 130 patients at multiple dialysis centers in the United States. The primary end points of the study are to evaluate SFP at varying dosage levels in hemodialysis patients and to determine the optimal concentration of SFP in dialysate that will maintain iron balance within their target hemoglobin range. Secondary end points include evaluating efficacy for changes in hemoglobin levels over time, reticulocyte hemoglobin content, incidence of systemic infection episodes and to quantify the amount of SFP iron transferred from the dialysate directly to the blood during the dialysis session.

Robert L. Chioini, Chairman and CEO of Rockwell stated, “Beginning the successful dosing of dialysis patients is another significant milestone in our clinical path for gaining FDA market approval for SFP. Going forward, we anticipate sharing news of our clinical progress as it becomes available.”

About Soluble Ferric Pyrophosphate (SFP)

Rockwell's proprietary iron-delivery product, SFP, is a soluble form of iron designed to provide physiological iron- maintenance therapy in ESRD patients by delivering iron via dialysate during dialysis treatments. SFP is a highly stable and non-polymeric iron salt and is designed to be administered directly into the bloodstream, overcoming the need for iron release from reticuloendothelial stores in the liver and other organs. The ferric iron core is tightly chelated to a pyrophosphate shell, that facilities transfer of iron from transferrin to ferritin, by-passing the liver. Compared to intravenous (IV) iron administration, previous human clinical study results indicate that SFP can deliver iron (via dialysate) safely and effectively and can maintain iron balance in dialysis patients within the target range, while at the same time decreasing associated nursing and pharmaceutical IV iron administration costs. Recent academic studies have shown that more frequent maintenance doses of iron improve the therapeutic benefits of recombinant erythropoietin treatments.

Rockwell has licensed the exclusive world-wide rights to SFP and is seeking FDA market approval. Patents for SFP have been secured in the United States, Japan and the European Union covering the three largest commercial markets for iron supplementation. Rockwell estimates that the U.S. dialysis market for IV iron delivery is approximately $450 million annually while the global market potential is approximately $750 million annually.

About Rockwell Medical

Rockwell Medical Technologies, Inc. is a leading, innovative manufacturer and developer of concentrates and specialty pharmaceuticals focused on improving the quality of care for dialysis patients. Dialysis is a process that duplicates kidney function for those patients whose kidneys have failed to work and who suffer from chronic kidney failure, a condition also known as end-stage-renal-disease (ESRD). There are an estimated 360,000 ESRD patients in the United States growing approximately 4-5% on average each year. There are approximately 2 million ESRD patients world-wide. Rockwell's products are used to maintain life, cleaning blood and replacing nutrients in the dialysis patient's bloodstream. Rockwell has licensed and is currently developing proprietary formulations for both iron-delivery and carnitine/vitamin-delivery utilizing its dialysate as the delivery mechanism. These novel technologies are designed to deliver safe and effective renal therapy to ESRD patients while decreasing nursing time and supply cost. The Company offers the proprietary Dri-Sate® Dry Acid Concentrate Mixing System, RenalPure® Liquid Acid Concentrate, SteriLyte® Liquid Bicarbonate Concentrate, RenalPure® Powder Bicarbonate Concentrate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. When we use words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "projected," "intend" or similar expressions, or make statements regarding our intent, belief, or current expectations, we are making forward-looking statements. While we believe these forward-looking statements are reasonable, you should not place undue reliance on any such forward-looking statements which are based on information available to us on the date of this release. Because these forward looking statements are based upon estimates and assumptions that are subject to significant business, economic and competitive uncertainties, many of which are beyond our control or are subject to change, actual results could be materially different. Factors which could cause such a difference include, without limitation, the risk factors set forth in the Company's SEC filings, including its Form 10-Q for the quarter ended June 30, 2007 and its Form 10-KSB for the year ended December 31, 2006. The forward- looking statements should be considered in light of these risks and uncertainties. We do not undertake, and expressly disclaim any obligation, to update or alter our statements whether as a result of new information, future events or otherwise, except as required by law.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative manufacturer and developer of concentrates and specialty pharmaceuticals focused on the end-stage-renal-disease market (ESRD), announced today that it has commenced enrollment in its Phase IIb dose-ranging study for Soluble Ferric Pyrophosphate (SFP), a physiological iron-maintenance therapy drug.

The Phase IIb dose-ranging study is a nine-month, controlled multi-center, double-blind study consisting of up to 130 patients at multiple dialysis centers in the United States. Patients will receive SFP during their normal three times/week dialysis regimen. The primary objectives of this study are to evaluate both safety and efficacy of SFP at varying dosage levels and to determine the optimal concentration of SFP that will maintain iron balance within the target hemoglobin range, in patients undergoing hemodialysis. Secondary endpoints include evaluating efficacy for changes in hemoglobin levels over time, reticulocyte hemoglobin content, incidence of systemic infection episodes and to quantify the amount of SFP iron transferred from the dialysate directly to the blood during the dialysis session. Results of this Phase IIb study are expected by the end of 2008.

Robert L. Chioini, Chairman and CEO of Rockwell stated, “We are excited to initiate this important step in our clinical development plan for SFP, a key product in Rockwell's renal drug development pipeline. The completion of this study will enable us to initiate our planned Phase III pivotal study program for FDA market approval of SFP.” Mr. Chioini also stated, “We have assembled a team of top-tier investigators who will be conducting this important work. Dosing is expected to begin in less than two weeks. As information is obtained from our Data Safety Monitoring Board it will be presented to the scientific and investment communities.”

Enrollment in the Phase IIb dose ranging study commenced following successful completion of an extensive pre-clinical safety, pharmacology and toxicology study program.

About Soluble Ferric Pyrophosphate (SFP)

Rockwell's proprietary iron-delivery product, SFP, is a soluble form of iron designed to provide physiological iron- maintenance therapy in ESRD patients by delivering iron via dialysate during dialysis treatments. SFP is a highly stable and non-polymeric iron salt and is designed to be administered directly into the bloodstream, overcoming the need for iron release from reticuloendothelial stores in the liver and other organs. The ferric iron core is tightly chelated to a pyrophosphate shell, that facilities transfer of iron from transferrin to ferritin, by-passing the liver. Based on previous human clinical study results, and compared to intravenous (IV) iron administration, Rockwell has shown that SFP can deliver iron via dialysate as a safe and effective method for maintaining iron balance in dialysis patients within the target iron range, while at the same time decreasing associated nursing and pharmaceutical IV iron administration costs. Recent academic studies have shown that more frequent maintenance doses of iron improve the therapeutic benefits of recombinant erythropoietin treatments.

Rockwell has licensed the exclusive world-wide rights to the SFP and is collaborating with the FDA in its development. Patents for SFP have been secured in the United States, Japan and the European Union covering the three largest commercial markets for iron supplementation. Rockwell estimates that the U.S. dialysis market for IV iron delivery is approximately $450 million annually while the global market potential is approximately $750 million annually.

About Rockwell Medical

Rockwell Medical Technologies, Inc. is a leading, innovative manufacturer and developer of concentrates and specialty pharmaceuticals focused on improving the quality of care for dialysis patients. Dialysis is a process that duplicates kidney function for those patients whose kidneys have failed to work and who suffer from chronic kidney failure, a condition also known as end-stage-renal-disease (ESRD). There are an estimated 360,000 ESRD patients in the United States growing approximately 4-5% on average each year. There are approximately 2 million ESRD patients world-wide. Rockwell's products are used to maintain life, cleaning blood and replacing nutrients in the dialysis patient's bloodstream. Rockwell has licensed and is currently developing proprietary formulations for both iron-delivery and carnitine/vitamin-delivery utilizing its dialysate as the delivery mechanism. These novel technologies are designed to deliver safe and effective renal therapy to ESRD patients while decreasing nursing time and supply cost. The Company offers the proprietary Dri-Sate® Dry Acid Concentrate Mixing System, RenalPure® Liquid Acid Concentrate, SteriLyte® Liquid Bicarbonate Concentrate, RenalPure® Powder Bicarbonate Concentrate, Blood Tubing Sets, Fistula Needles and a wide range of ancillary dialysis items.

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. When we use words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "projected," "intend" or similar expressions, or make statements regarding our intent, belief, or current expectations, we are making forward-looking statements. While we believe these forward-looking statements are reasonable, you should not place undue reliance on any such forward-looking statements which are based on information available to us on the date of this release. Because these forward looking statements are based upon estimates and assumptions that are subject to significant business, economic and competitive uncertainties, many of which are beyond our control or are subject to change, actual results could be materially different. Factors which could cause such a difference include, without limitation, the risk factors set forth in the Company's SEC filings, including its Form 10-Q for the quarter ended June 30, 2007 and its Form 10-KSB for the year ended December 31, 2006. The forward- looking statements should be considered in light of these risks and uncertainties. We do not undertake, and expressly disclaim any obligation, to update or alter our statements whether as a result of new information, future events or otherwise, except as required by law.

WIXOM, Mich. -- Rockwell Medical Technologies, Inc., a leading, innovative manufacturer and developer of hemodialysis products and specialty pharmaceuticals focused on improving the quality of care for dialysis patients in the end-stage-renal-disease (ESRD) market, reported record quarterly sales of $10.5 million for the second quarter of 2007, up 80% over the second quarter of 2006. Sales for the first half of 2007 increased 66% compared to the first half of 2006. Second quarter loss per share was ($.04) compared to ($.13) in the second quarter last year. Rockwell's second quarter loss of ($476,625) included research and development expense of $761,539 for the Company's physiological iron maintenance therapy drug (SFP).

Second Quarter Highlights:

• Sales increased 80% compared to second quarter 2006.
• Sequential revenue growth of 11.3% over the first quarter.
• Continued domestic market share gains in the second quarter.
• Second quarter loss of ($476,625) including R&D costs of $761,539.
• Gross profit margins of 10.6% increased 2.7% over the second quarter of 2006.
• Net loss was ($.04) per share; an improvement of $.10 per share over the first quarter of 2007.

• Sales increased 66% in the first half of 2007 compared to the first half of 2006.
• Domestic dialysis centers serviced increased over 50% in 2007.
• Net Loss of ($2.1) million included R&D expense of $1.6 million.
• Upgraded to the Nasdaq Global Market Exchange.

• Completed pre-clinical safety pharmacology and toxicology studies for SFP.
• Received final non-clinical study reports demonstrating a strong safety profile for SFP.
• Completed selection of clinical trial sites for dose ranging study.
• Granted SFP patent in Japan, the second largest national ESRD market after the United States.

Mr. Robert L. Chioini, Chairman and Chief Executive Officer of Rockwell Medical Technologies, Inc. stated, “This quarter our sales continued to increase as expected and our gross profit margins recovered to historical levels. We continued to experience aggressive growth in our domestic business coupled with significant price increases to our customer base, which were necessitated by high inflation in our key raw material components and distribution costs. Going forward, we anticipate end-user prices continuing to increase due to raw material costs being driven higher by increased global energy costs.”

He also stated, “Development of SFP has progressed as expected in the second quarter. We are on target to commence enrollment in our Dose Ranging Study in the U.S. in September. In addition, we received patent issuance in Japan, which we view as an attractive market for SFP”

Rockwell will be hosting a conference call to review its second quarter results on Tuesday, August 14, 2007 at 11:00 am EDT. Investors are encouraged to call in several minutes in advance at (877) 704-5381 to hear the call or they may listen on the web at the following link: http://investor.shareholder.com/media/index.cfm?c=RMTI&e=1&mediakey=A2FAB283B25BD82A09AC1C359F047CEF

See www.rockwellmed.com for more details and playback options.

Rockwell Medical Technologies, Inc. is a leading, innovative manufacturer and developer of concentrates and specialty pharmaceuticals focused on improving the quality